Biomedical subjects
Publications and source records attributed to D Mattox.
A patient presenting with progressive pulsatile tinnitus was found to have an ipsilateral dural sinus stenosis. This problem was successfully treated by an endovascular approach with angioplasty and subsequent sinus stenting. The diagnostic evaluation, therapeutic method, and follow-up concerning this problem and its treatment are discussed.
Previous reports have indicated that optokinetic afternystagmus (OKAN) becomes asymmetric after the occurrence of unilateral peripheral vestibular lesions, and suggested that OKAN may be used for localizing the side of the lesion. These studies did not take into account spontaneous nystagmus. We compared OKAN in 12 subjects with unilateral vestibular loss after resection of acoustic neuroma to OKAN in 30 normal subjects. After offsetting the data for spontaneous nystagmus, we calculated the initial amplitude, the time constant, and the slow-phase cumulative eye position (SCEP) parameters of OKAN. The directional asymmetry of parameters to rightward and leftward stimulation were also calculated. The mean SCEP, initial amplitude, and time constant parameters were reduced significantly in the patients, and each also showed a directional asymmetry, such that they were greater for stimulation toward the side of the lesion. The directional preponderance of the SCEP parameter had the highest sensitivity for the side of the lesion, being abnormally elevated in 58.3% of patients with unilateral loss. We conclude that OKAN might be useful in combination with other subtests of a battery, but that by itself OKAN is only moderately sensitive to unilateral peripheral vestibular loss.
Ameloblastoma is an aggressive locally recurring neoplasm of odontogenic epithelium. We describe a case of a mandibular ameloblastoma with a 17-year history of local recurrences followed by two metachronous intracranial metastases. Central nervous system metastasis without pulmonary involvement is previously unreported in a living patient with ameloblastoma. The behavior of this tumor qualifies it as a malignant ameloblastoma.
Retinoids, the analogs of vitamin A, are active in vitro and in vivo against squamous cell carcinoma in animals and against certain epithelial precancers and cancers in humans. These data led us to design a prospective, multi-institutional, randomized phase II trial of isotretinoin in advanced head and neck squamous cell carcinoma. We randomly assigned 40 patients to receive isotretinoin or methotrexate, the best-studied and most active single agent for this disease. Overall, the study patients had extremely poor prognoses, i.e., low performance statuses and recurring disease after surgery and/or irradiation. Three objective responses (16%), including one complete response, occurred in the 19 evaluable isotretinoin-treated patients. Only one minor response (5%) occurred in the methotrexate-treated group. Toxicity occurred with both drugs, but was manageable and never life threatening in the retinoid group. These results and the established activity of retinoids in oral leukoplakia (a precursor of head and neck cancer) indicate the need for further study of this class of drugs in head and neck cancer.
In 1980, the Southwest Oncology Group instituted a multi-institutional, prospective, randomized phase III trial to evaluate whether inductive chemotherapy improved survival in patients with advanced stage resectable squamous cell carcinoma of the head and neck. From a group of 158 eligible patients, 76 were randomized to conventional treatment (surgery and postoperative radiotherapy), and 82 were assigned to experimental treatment (induction chemotherapy, surgery, postoperative radiotherapy). Median follow-up for living patients was approximately 5 years. These analyses include chemotherapy responses and toxicities, surgical complications, radiotherapy toxicities, patient compliance, survival time, and patterns of treatment failure. Overall chemotherapy response was 0.70 (0.19 CR, 0.51 PR). The median survival time for conventional treatment was longer than the time for patients receiving preoperative chemotherapy, although the survival time differences were not statistically significant. This final analysis demonstrates no benefit in survival using preoperative chemotherapy for advanced stage, resectable head and neck squamous cell carcinoma.
Explore the source record for details and available documents.